RU2002116251A - Аэрозольная композиция, содержащая формотерол - Google Patents
Аэрозольная композиция, содержащая формотеролInfo
- Publication number
- RU2002116251A RU2002116251A RU2002116251/15A RU2002116251A RU2002116251A RU 2002116251 A RU2002116251 A RU 2002116251A RU 2002116251/15 A RU2002116251/15 A RU 2002116251/15A RU 2002116251 A RU2002116251 A RU 2002116251A RU 2002116251 A RU2002116251 A RU 2002116251A
- Authority
- RU
- Russia
- Prior art keywords
- component
- use according
- carrier
- dry powder
- diluent
- Prior art date
Links
- 229960002848 formoterol Drugs 0.000 title claims 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title claims 4
- 239000000443 aerosol Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000843 powder Substances 0.000 claims 8
- 239000003085 diluting agent Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 2
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Применение сухого порошка, содержащего (А) формотерол или его фармацевтически приемлемую соль, или сольват, или сольват указанной соли и (Б), состоящий из отдельных частиц фармацевтически приемлемый разбавитель или носитель в количестве от 400 до 5000 мкг на 1 мкг компонента (А), для приготовления лекарственного средства, вводимого путем ингаляции, которое предназначено для лечения хронического обструктивного заболевания легких.
2. Применение сухого порошка, содержащего (А) формотерол или его фармацевтически приемлемую соль, или сольват, или сольват указанной соли и (Б), состоящий из отдельных частиц фармацевтически приемлемый разбавитель или носитель в количестве от 400 до 5000 мкг на 1 мкг компонента (А), где сухой порошок практически не содержит пропионат флутиказона, фуроат мометазона пли солей тиотропия, для приготовления лекарственного средства, вводимого путем ингаляции, которое предназначено для лечения хронического обструктивного заболевания легких.
3. Применение по п.1 или 2, где формотерол (А) находится в форме дигидрата фумарата формотерола.
4. Применение сухого порошка, состоящего или практически состоящего из (А) дигидрата фумарата формотерола и (Б) фармацевтически приемлемого разбавителя или носителя в количестве от 400 до 5000 мкг на 1 мкг компонента (А), для приготовления лекарственного средства, вводимого путем ингаляции, которое предназначено для лечения хронического обструктивного заболевания легких.
5. Применение по любому из предыдущих пунктов, где разбавитель или носитель (Б) представляет собой сахарид и/или сахарный спирт.
6. Применение по п.5, где разбавитель или носитель (Б) представляет собой лактозу.
7. Применение по любому из предыдущих пунктов, где разбавитель или носитель (Б) присутствует в количестве от 800 до 3000 мкг на 1 мкг компонента (А).
8. Применение по любому из предыдущих пунктов, где средний диаметр частиц компонента (А) составляет не более 10 мкм.
9. Применение по любому из предыдущих пунктов, где сухой порошок находится в капсуле, причем капсула содержит стандартную дозу компонента (А).
10. Применение по п.9, где капсула содержит 12 мкг компонента (А) и 19988-24988 мкг разбавителя или носителя (Б).
11. Применение по любому из пп.1-8, где сухой порошок находится в резервуаре ингалятора для сухого порошка, вмещающего несколько доз, приспособленного для введения при однократном нажатии такого количества порошка, которое содержит стандартную дозу компонента (А).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9928311.1A GB9928311D0 (en) | 1999-11-30 | 1999-11-30 | Organic compounds |
| GB9928311.1 | 1999-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002116251A true RU2002116251A (ru) | 2004-01-20 |
| RU2327452C2 RU2327452C2 (ru) | 2008-06-27 |
Family
ID=10865451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002116251/15A RU2327452C2 (ru) | 1999-11-30 | 2000-11-28 | Аэрозольная композиция, содержащая формотерол |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US6887459B1 (ru) |
| EP (3) | EP3050558A1 (ru) |
| JP (3) | JP2003515551A (ru) |
| KR (1) | KR100771281B1 (ru) |
| CN (1) | CN1399540A (ru) |
| AU (1) | AU769765B2 (ru) |
| BR (1) | BR0015908A (ru) |
| CA (1) | CA2389349C (ru) |
| CZ (1) | CZ20021850A3 (ru) |
| ES (1) | ES2178943B1 (ru) |
| FR (1) | FR2801506B1 (ru) |
| GB (1) | GB9928311D0 (ru) |
| HU (1) | HUP0203728A3 (ru) |
| IL (2) | IL149362A0 (ru) |
| IT (1) | ITMI20002556A1 (ru) |
| MX (1) | MXPA02005384A (ru) |
| NO (1) | NO20021963L (ru) |
| NZ (1) | NZ518873A (ru) |
| PL (1) | PL354974A1 (ru) |
| RU (1) | RU2327452C2 (ru) |
| SK (1) | SK7432002A3 (ru) |
| TW (1) | TWI278324B (ru) |
| WO (1) | WO2001039745A2 (ru) |
| ZA (1) | ZA200204147B (ru) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| GB9928311D0 (en) * | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| KR100947409B1 (ko) * | 2002-03-01 | 2010-03-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 포모테롤 초미세 조성물 |
| AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
| NZ538965A (en) | 2002-08-21 | 2006-11-30 | Norton Healthcare Ltd | Dry powder inhalation compositions |
| GB0219511D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| JP2006516531A (ja) * | 2002-08-21 | 2006-07-06 | ノートン ヘルスケアー リミテッド | 吸入組成物 |
| GB0312148D0 (en) | 2003-05-28 | 2003-07-02 | Aventis Pharma Ltd | Stabilized pharmaceutical products |
| GB0315889D0 (en) | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| ES2245612B1 (es) * | 2004-06-29 | 2007-08-16 | Universidad De Barcelona | Nuevo uso terapeutico del formoterol. |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
| AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| DK1986679T3 (da) | 2006-02-22 | 2017-11-20 | Mannkind Corp | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof |
| GB0616299D0 (en) * | 2006-08-16 | 2006-09-27 | Cambridge Consultants | Drug Capsules for dry power inhalers |
| GB0617171D0 (en) * | 2006-08-31 | 2006-10-11 | Generics Uk Ltd | Novel compositions and methods |
| JP2010519195A (ja) | 2007-02-19 | 2010-06-03 | シプラ・リミテッド | 薬学的組成物 |
| CN101342155B (zh) * | 2007-07-11 | 2012-01-04 | 天津帝士力投资控股集团有限公司 | 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法 |
| US20100055045A1 (en) * | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| CA2716936C (en) * | 2008-02-26 | 2018-06-05 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| CN103252007B (zh) | 2008-06-13 | 2016-06-22 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP2676695A3 (en) | 2009-03-11 | 2017-03-01 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| KR101875969B1 (ko) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
| SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| EP2970149B1 (en) | 2013-03-15 | 2019-08-21 | MannKind Corporation | Microcrystalline diketopiperazine compositions and methods |
| CN105451716A (zh) | 2013-07-18 | 2016-03-30 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
| WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
| WO2015065220A1 (ru) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |
| WO2015065221A1 (ru) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| GB8911259D0 (en) * | 1989-05-17 | 1989-07-05 | Fisons Plc | Inhalation medicament |
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| WO1993011773A1 (en) * | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
| JP2736168B2 (ja) * | 1992-03-10 | 1998-04-02 | フアイソンズ・ピーエルシー | 医薬製剤 |
| SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| SE9700134D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| SA95160463B1 (ar) * | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
| US6182655B1 (en) | 1995-12-07 | 2001-02-06 | Jago Research Ag | Inhaler for multiple dosed administration of a pharmacological dry powder |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| AU738192B2 (en) | 1997-09-19 | 2001-09-13 | Neuren Pharmaceuticals Limited | Neuronal rescue agent |
| GB9805102D0 (en) | 1998-03-10 | 1998-05-06 | Ciba Geigy Ag | Device |
| GB9806462D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved compositions for inhalation |
| GB9807232D0 (en) * | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| GB9928311D0 (en) * | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
-
1999
- 1999-11-30 GB GBGB9928311.1A patent/GB9928311D0/en not_active Ceased
-
2000
- 2000-11-08 TW TW089123621A patent/TWI278324B/zh not_active IP Right Cessation
- 2000-11-27 FR FR0015277A patent/FR2801506B1/fr not_active Expired - Lifetime
- 2000-11-28 IL IL14936200A patent/IL149362A0/xx unknown
- 2000-11-28 PL PL00354974A patent/PL354974A1/xx not_active IP Right Cessation
- 2000-11-28 EP EP16157997.4A patent/EP3050558A1/en not_active Withdrawn
- 2000-11-28 HU HU0203728A patent/HUP0203728A3/hu not_active Application Discontinuation
- 2000-11-28 KR KR1020027006847A patent/KR100771281B1/ko not_active Expired - Fee Related
- 2000-11-28 CZ CZ20021850A patent/CZ20021850A3/cs unknown
- 2000-11-28 EP EP00993236A patent/EP1233757A2/en not_active Ceased
- 2000-11-28 BR BR0015908-5A patent/BR0015908A/pt not_active Application Discontinuation
- 2000-11-28 IT IT2000MI002556A patent/ITMI20002556A1/it unknown
- 2000-11-28 AU AU28374/01A patent/AU769765B2/en not_active Ceased
- 2000-11-28 JP JP2001541478A patent/JP2003515551A/ja not_active Withdrawn
- 2000-11-28 MX MXPA02005384A patent/MXPA02005384A/es active IP Right Grant
- 2000-11-28 WO PCT/EP2000/011894 patent/WO2001039745A2/en not_active Ceased
- 2000-11-28 NZ NZ518873A patent/NZ518873A/en not_active IP Right Cessation
- 2000-11-28 CN CN00816245A patent/CN1399540A/zh active Pending
- 2000-11-28 CA CA002389349A patent/CA2389349C/en not_active Expired - Fee Related
- 2000-11-28 SK SK743-2002A patent/SK7432002A3/sk not_active Application Discontinuation
- 2000-11-28 US US10/148,043 patent/US6887459B1/en not_active Expired - Lifetime
- 2000-11-28 EP EP08164295A patent/EP2011484A3/en not_active Ceased
- 2000-11-28 RU RU2002116251/15A patent/RU2327452C2/ru active
- 2000-11-30 ES ES200002868A patent/ES2178943B1/es not_active Expired - Fee Related
-
2002
- 2002-04-25 IL IL149362A patent/IL149362A/en not_active IP Right Cessation
- 2002-04-25 NO NO20021963A patent/NO20021963L/no not_active Application Discontinuation
- 2002-05-24 ZA ZA200204147A patent/ZA200204147B/xx unknown
-
2005
- 2005-02-16 US US11/059,041 patent/US20050136010A1/en not_active Abandoned
-
2007
- 2007-03-20 US US11/725,903 patent/US20070196286A1/en not_active Abandoned
-
2013
- 2013-01-04 JP JP2013000092A patent/JP2013075909A/ja not_active Withdrawn
-
2015
- 2015-03-04 JP JP2015042930A patent/JP2015108020A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002116251A (ru) | Аэрозольная композиция, содержащая формотерол | |
| US5642728A (en) | System for dispensing pharmaceutically active compounds | |
| US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
| US6250300B1 (en) | System for dispensing pharmaceutically active compounds | |
| RU2767062C2 (ru) | Составы, устройства и способы для лечения алкогольной зависимости | |
| RU2001123923A (ru) | Композиции, включающие формотерол и соль тиотропия | |
| RU2001126347A (ru) | Композиции, включающие формотерол и фуроат мометасона, предназначенные для лечения астмы | |
| US20060254583A1 (en) | Dry powder inhaler system | |
| JP2002538110A5 (ru) | ||
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| JP2004500429A (ja) | チオトロピウム及びロフレポニドを含む医薬用の組み合わせ | |
| RU2006132038A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| CN107205936B (zh) | 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物 | |
| SE527190C2 (sv) | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid | |
| UA119774C2 (uk) | Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл) | |
| JP2005508963A (ja) | 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ | |
| RU2008124825A (ru) | Органические соединения, включающие соль гликопиррония | |
| KR20040099436A (ko) | 건조 분말 조성물 | |
| US20050152847A1 (en) | Novel formulation | |
| SE527200C2 (sv) | Inhalatoranordning samt kombinerade doser av formaterol och fluticason | |
| RU2020112519A (ru) | Ингалятор и сетка для ингалятора | |
| US20050063911A1 (en) | Combined doses of formoterol and an anticholinergic agent | |
| SE527191C2 (sv) | Inhalatoranordning samt kombinerade doser av tiotropium och fluticason | |
| JP2004500431A (ja) | （ｒ，ｒ）−ホルモテロール及びロフレポニドを含む医薬組成物 | |
| JP2004523536A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20140127 |